
Please try another search
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies’ technologies and collection of information concerning clinical trial. It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Yutaka Ogihara | 57 | 2011 | President, CEO & Chairman |
Noriyuki Shikanai | 77 | 2013 | Independent Outside Director |
Takao Yamaguchi | 71 | 2015 | Outside Audit & Supervisory Board Member |
Hiromi Watanabe | 78 | 2019 | Independent Outside Director |
Ken Shigematsu | 77 | 2017 | Independent Outside Director |
Kensuke Morita | 59 | 2022 | Outside Audit & Supervisory Board Member |
Yukio Ikemura | 67 | 2022 | Outside Audit & Supervisory Board Member |
Yasuji Kurose | 55 | 2023 | CFO, Chief Strategy Officer, Director of Corporate Planning & Executive Director |
Michiro Onota | 65 | 2018 | CMO, Chairman of KYORIN Pharmaceutical Group Facilities Co., Ltd. & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review